Breaking News Instant updates and real-time market news.

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

, RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

13:17
11/21/18
11/21
13:17
11/21/18
13:17

Aquestive under pressure after generic Suboxone patent decision

Shares of Aquestive Therapeutics (AQST) are sliding after Dr. Reddy's Laboratories (RDY) announced that the U.S. Court of Appeals for the Federal Circuit issued a decision in favor of the latter, vacating the District Court's preliminary injunction that had prohibited Dr. Reddy's from selling its generic version of Indivior's Suboxone. While noting that the Aquestive selloff appears "meaningfully overdone," RBC Capital analyst Randall Stanicky believes this will impact the milestones that the company receives from Indivior, with the remaining milestones now unlikely. Meanwhile, his peer at BMO Capital sees the situation as fluid and "very manageable." BUPRENORPHINE, NALOXONE LITIGATION: Last night, Dr. Reddy's Laboratories along with its subsidiaries announced that the U.S. Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy's Laboratories, concluding that Indivior had not shown that it is likely to succeed on the merits of its infringement case on U.S. Patent No. 9,931,305. This decision vacates the District Court's preliminary injunction that had prohibited Dr. Reddy's from selling its generic version of Suboxone sublingual film. As a result of the ruling, Dr. Reddy's will resume its launch activities "as soon as permitted". In a statement following the news, Aquestive Therapeutics said that, "While we are disappointed by the court's decision, we will continue to work with Indivior to vigorously pursue ongoing infringement cases against DRL and other generic manufacturers in order to protect the Suboxone patent portfolio. [Yesterday's] action does nothing to change the validity and assertability of any of the patents in our portfolio." AQUESTIVE SELLOFF OVERDONE: In a research note to investors, RBC Capital's Stanicky argued that the decision to lift the preliminary injunction on Dr. Reddy's launching a generic version of Suboxone will impact the milestones that Aquestive receives from Indivior, with the remaining milestones now unlikely. However, he noted that Suboxone in total comprises about $3 per share in value in his model, which is meaningfully less than the two-day selloff of $7 in the stock, which makes the pullback "meaningfully overdone." Looking ahead, the analyst believes the focus for Aquestive is on the proprietary side of its business, including the recent launch of Sympazan oral film. Stanicky reiterated an Outperform rating and $24 price target on Aquestive shares. LOSS ON SUBOXONE APPEAL 'MANAGEABLE': Also commenting on the news, BMO Capital analyst Gary Nachman said that while the appeals court ruling "disappointing and surprising," and could trigger an at-risk launch by Dr. Reddy's, the situation is fluid and "very manageable." Acknowledging that there is "certainly a possibility" Indivior and Dr. Reddy's could settle, the analyst also noted that it is not completely clear if that would trigger accelerated launches of generic Suboxone from Mylan (MYL) and Endo International (ENDP)/Par. Overall, Nachman believes that Aquestive's ex-U.S. Suboxone revenue, while currently small, is a much bigger driver of long-term value. The analyst reiterated an Outperform rating and $26 price target on Aquestive shares. PRICE ACTION: In afternoon trading, shares of Aquestive have dropped over 23% to $10.11, while Dr. Reddy's stock is fractionally down to $36.36.

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

MYL

Mylan

$33.29

-0.65 (-1.92%)

ENDP

Endo

$12.39

-0.14 (-1.12%)

  • 27

    Nov

  • 02

    Dec

  • 04

    Dec

  • 29

    Jan

AQST Aquestive Therapeutics
$10.12

-3.05 (-23.16%)

09/13/18
WEDB
09/13/18
INITIATION
Target $33
WEDB
Outperform
Aquestive Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started coverage of Aquestive Therapeutics with an Outperform rating and $33 price target. The analyst considers Aquestive Therapeutics to be an opportunity to invest in proprietary PharmFilm technology being leveraged to develop a pipeline of 10 drugs and candidates and to provide an oral alternative in patients having difficulty swallowing pills or only having invasive options like injections.
11/19/18
JMPS
11/19/18
NO CHANGE
Target $31
JMPS
Outperform
Aquestive CRL for 'peripheral' program has no read-through, says JMP Securities
After the FDA issued a CRL for Aquestive Therapeutics' tadalafil oral film candidate, JMP Securities analyst Jason Butler said he did not have this "peripheral" product in his valuation for Aquestive shares and he does not believe it is a major focus for investors. The issues raised by FDA appear specific to this product and he does not see any negative read-through to the company's other programs, Butler tells investors. He maintains an Outperform rating and $31 price target on Aquestive shares.
11/21/18
RBCM
11/21/18
NO CHANGE
Target $24
RBCM
Outperform
Aquestive selloff on generic Suboxone decision overdone, says RBC Capital
RBC Capital analyst Randall Stanicky attributes the added pressure on Aquestive Therapeutics (AQST) shares to yesterday's decision to lift the preliminary injunction on Dr. Reddy's (RDY) launching a generic version of Suboxone. He notes this will impact the milestones that Aquestive receives from Indivior, with the remaining milestones now unlikely. However, he notes that Suboxone in total comprises about $3 per share in value in his model, which is meaningfully less than the two-day selloff of $7 in the stock, which makes the pullback "meaningfully overdone" in his view. Stanicky has an Outperform rating on Aquestive shares with a $24 price target.
11/21/18
BMOC
11/21/18
NO CHANGE
Target $26
BMOC
Outperform
BMO says Aquestive loss on Suboxone appeal disappointing but manageable
BMO Capital analyst Gary Nachman noted that Aquestive Therapeutics (AQST) partner Indivior lost an appeals court ruling regarding the preliminary injunction that previously prevented Dr. Reddy's (RDY) from selling its generic version of Suboxone sublingual film. While he said the decision is disappointing and surprising, and could trigger an at-risk launch by Dr. Reddy's, Nachman sees the situation as fluid and "very manageable." There is certainly a possibility Indivior and Dr. Reddy's could settle, said the analyst, who adds that ex-U.S. Suboxone revenue, while currently small, is a much bigger driver of long-term value. Nachman has an Outperform rating and $26 price target on Aquestive shares.
RDY Dr. Reddy's
$36.37

-0.11 (-0.30%)

03/27/18
EVER
03/27/18
NO CHANGE
Target $155
EVER
Outperform
Evercore sees higher chances of Revlimid patent settlement for Celgene
Evercore ISI analyst Umer Raffat believes the odds of a Revlimid patent settlement between Celgene (CELG) and Dr. Reddy's (RDY) have gone up "considerably" following a recent court filing. The filing, according to the analyst, shows Dr. Reddy's agreed to resolve claims construction issues, which he believes "implies a clear alignment in thought process between both sides." A potential settlement on Revlimid remains the biggest catalyst on Celgene in 2018, and could lead a quick re-rating in the valuation multiple, Raffat tells investors in a research note. He keeps Celgene as his top pick for 2018 with an Outperform rating and $155 price target.
05/29/18
RHCO
05/29/18
NO CHANGE
Target $96
RHCO
Hold
Celgene price target lowered to $96 from $106 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on Celgene (CELG) to $96 after last week's R&D meeting hosted by the management, which "highlighted" the importance of the multiple myeloma program to the company, its research into the mechanism of iMiD drugs, and its pursuit of anti-B-cell maturation antigen in treatment function. The analyst believes that while the company can sustain its position of leadership in myeloma, he is concerned with the overhang on the stock coming from intellectual property litigation on Revlimid, anticipating the stock to remain rangebound until next week's likely generic Revlimid settlement with Dr. Reddy's (RDY).
MYL Mylan
$33.29

-0.65 (-1.92%)

11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/18
ARGS
11/15/18
UPGRADE
Target $42
ARGS
Buy
Mylan upgraded to Buy from Hold at Argus
Argus analyst Jasper Hellweg upgraded Mylan to Buy with a price target of $42, saying the stock appears to be close to an inflection after several quarters of underperformance. The analyst points to the company's Q3 earnings beat and its gross margin expansion of 280bps. Hellweg further cites Mylan's launch of a "record number of new generic and biosimilar products this year, significantly diversifying its portfolio" whereby no single product now accounts for more than 3% of revenue. The analyst also keeps his FY18 EPS view at $4.73 and nudges his FY19 outlook higher by 2c to $5.28 while noting the company's forward earnings multiple of 6.8-times, which is near the low end of its 5.8- to 16.3-times historical average.
11/06/18
WELS
11/06/18
UPGRADE
Target $40
WELS
Outperform
Wells upgrades Mylan to Outperform, sees more upside after today's rally
Wells Fargo analyst David Maris upgraded Mylan (MYL) to Outperform from Market Perform with an unchanged price target of $40. The stock in afternoon trading is up 18%, or $5.76, to $37.13. Mylan shares have underperformed the S&P 500 Index for the year-to-date, one year, two year, and five year periods and the shares trade at a discount to peer Teva (TEVA), Maris tells investors in a research note titled "Concerns Abound, but Valuation Attractive." The analyst, however, believes Mylan is positioned for near-term outperformance after the company maintained its 2018 earnings guidance. Maris previously saw risk to second half of 2018 estimates, but with today's Q3 results, he now believes the risk to the downside to Q4 estimates is lower than previously thought. Further, Mylan's statement that Q4 guidance can be achieved with or without new approvals "provides some upside to sentiment" if generic Advair or other approvals materialize, says the analyst. Maris thinks that even with today's rally, Mylan shares still have more than 10% additional upside potential to reach fair value.
11/15/18
ARGS
11/15/18
UPGRADE
ARGS
Buy
Mylan upgraded to Buy from Hold at Argus
ENDP Endo
$12.39

-0.14 (-1.12%)

11/09/18
ADAM
11/09/18
UPGRADE
Target $20
ADAM
Buy
Endo upgraded to Buy from Hold at Canaccord
Canaccord analyst Dewey Steadman upgraded Endo to Buy from Hold following its "beat and raise" quarter. He noted the strength was in its injectables and branded businesses and sees the recent pullback in the shares as a buying opportunity. Stedman raised his price target to $20 from $16 on Endo shares.
11/09/18
SBSH
11/09/18
NO CHANGE
Target $19
SBSH
Buy
Citi confused by post-earnings selloff in Endo shares
Citi analyst Liav Abraham admits she's "somewhat confused" by the selloff in shares of Endo International following the company's Q3 results. The company posted a "solid beat-and-raise quarter," which was accompanied by "constructive commentary" by management on the fundamentals of both the business and the generics industry, Abraham tells investors in a research note. She continues to see upside to Street estimates, though acknowledges the lack of color provided on the earnings call regarding dynamics heading into 2019 "could have led to some frustration amongst investors." The analyst keeps a Buy rating on Endo with a $19 price target.
11/08/18
HCWC
11/08/18
NO CHANGE
Target $81
HCWC
Buy
BioSpecifics price target raised to $81 from $72 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for BioSpecifics Technologies (BSTC) to $81 after Endo International (ENDP) reported positive results from two identical Phase 3 trials of Collagenase Clostridium Histolyticum, or Xiaflex, for the treatment of cellulite. Earlier this month, BioSpecifics reported positive top-line data from the Phase 1 trial of CCH for the treatment of uterine fibroids, says the analyst. He believes Endo's data from 845 women with moderate to severe cellulite in the U.S. could be a "catalytic milestone" for both Endo and BioSpecifics as there is no FDA approved injectable treatment for cellulite in the aesthetics industry. Selvaraju increased the probability of success from 70% to 85% for BioSpecifics' cellulite indication. It is also possible that Endo may acquire BioSpecifics, Selvaraju tells investors in a research note. He reiterates a Buy rating on BioSpecifics shares.
10/19/18
CANT
10/19/18
NO CHANGE
Target $18
CANT
Neutral
Endo price target raised to $18 from $12 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target for Endo International to $18 after speaking with four physicians that treat up to 50 patients per month for cellulite. All four physicians were "very positive" on Endo's Phase 2 data and expect a good outcome for its Phase 3 study. If CCH is approved, doctors believe it would be the best treatment for both dimpled and wavy/mattress cellulite, Chen tells investors in a research note. The analyst, however, keeps a Neutral rating on Endo, saying she thinks the risk/reward for the company's existing business and new opportunities is already accurately reflected in the stock price.

TODAY'S FREE FLY STORIES

IIPR

Innovative Industrial Properties

$90.00

-0.175 (-0.19%)

13:09
03/23/19
03/23
13:09
03/23/19
13:09
Periodicals
Innovative Industrial Properties flying high, Barron's says »

American cannabis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$129.80

-4.1 (-3.06%)

13:05
03/23/19
03/23
13:05
03/23/19
13:05
Periodicals
Investors missing how far Caterpillar dug into costs, Barron's says »

Caterpillar has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

MO

Altria Group

$55.90

-0.23 (-0.41%)

12:59
03/23/19
03/23
12:59
03/23/19
12:59
Periodicals
E-cigarettes not helping people quit smoking, Barron's says »

According to the CDC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

MAN

Manpower

$80.83

-5.02 (-5.85%)

, SABR

Sabre

$21.02

-0.62 (-2.87%)

12:51
03/23/19
03/23
12:51
03/23/19
12:51
Periodicals
Sabre, j2 Global among mid-cap stocks with sustainable dividends, Barron's says »

When it comes to…

MAN

Manpower

$80.83

-5.02 (-5.85%)

SABR

Sabre

$21.02

-0.62 (-2.87%)

WBS

Webster Financial

$48.90

-3.03 (-5.83%)

NATI

National Instruments

$44.16

-1.28 (-2.82%)

JCOM

j2 Global

$84.63

-1.95 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 10

    May

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

, GME

GameStop

$10.57

0.03 (0.28%)

12:47
03/23/19
03/23
12:47
03/23/19
12:47
Periodicals
Gaming meets the cloud as investors scramble to catch up, Barron's says »

The cloud will eventually…

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

GME

GameStop

$10.57

0.03 (0.28%)

AMD

AMD

$26.43

-1.47 (-5.27%)

SNE

Sony

$42.09

-1.915 (-4.35%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

  • 16

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

LYFT

Lyft

$0.00

(0.00%)

12:42
03/23/19
03/23
12:42
03/23/19
12:42
Periodicals
Investors should avoid booking ride when Lyft goes public, Barron's says »

Lyft will soon be going…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DIS

Disney

$108.30

-0.36 (-0.33%)

, AAPL

Apple

$191.11

-3.96 (-2.03%)

12:38
03/23/19
03/23
12:38
03/23/19
12:38
Periodicals
Streaming revolution too complicated, Barron's says »

The streaming revolution…

DIS

Disney

$108.30

-0.36 (-0.33%)

AAPL

Apple

$191.11

-3.96 (-2.03%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 11

    Apr

  • 25

    Apr

  • 08

    May

FB

Facebook

$164.25

-1.83 (-1.10%)

, GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

08:18
03/23/19
03/23
08:18
03/23/19
08:18
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$164.25

-1.83 (-1.10%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

TWTR

Twitter

$32.98

0.37 (1.13%)

GM

General Motors

$36.51

-0.84 (-2.25%)

AMD

AMD

$26.43

-1.47 (-5.27%)

INTC

Intel

$53.20

-1.41 (-2.58%)

MRVL

Marvell

$19.69

-1.11 (-5.34%)

MCHP

Microchip

$85.50

-1.83 (-2.10%)

MU

Micron

$41.68

-2.32 (-5.27%)

NVDA

Nvidia

$177.40

-6.52 (-3.55%)

QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

  • 04

    Jun

  • 05

    Jun

  • 27

    Oct

21:30
03/22/19
03/22
21:30
03/22/19
21:30
General news
Breaking General news story  »

Chicago Federal Reserve…

21:15
03/22/19
03/22
21:15
03/22/19
21:15
General news
Breaking General news story  »

Atlanta Federal Reserve…

PLNT

Planet Fitness

$66.76

-0.825 (-1.22%)

18:44
03/22/19
03/22
18:44
03/22/19
18:44
Hot Stocks
Planet Fitness CEO: We have a streamlined business model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRDM

Iridium

$26.40

-0.38 (-1.42%)

18:22
03/22/19
03/22
18:22
03/22/19
18:22
Hot Stocks
Iridium CEO: We've doubled our bottom line over the past eight years »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:05
03/22/19
03/22
18:05
03/22/19
18:05
General news
Sen. Sanders calls on White House to make Mueller report public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

, RNECY

Renesas

$0.00

(0.00%)

18:02
03/22/19
03/22
18:02
03/22/19
18:02
Hot Stocks
Integrated Device, Renesas receive final approval for merger »

Renesas Electronics…

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

RNECY

Renesas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:48
03/22/19
03/22
17:48
03/22/19
17:48
General news
Senator Warren urges AG Barr to release Mueller report to the public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.49

-10.2 (-2.74%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
Lawmaker urges FAA, Boeing workers to utilize whistleblower page »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

GLD

SPDR Gold Shares

$123.97

0.29 (0.23%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
SPDR Gold Shares holdings rise to 781.03MT from 778.09MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:40
03/22/19
03/22
17:40
03/22/19
17:40
General news
Weekly CFTC Commitment of Traders highlights »

10-YEAR U.S. TREASURY net…

ONEXF

Onex

$0.00

(0.00%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Onex to acquire Gluskin Sheff »

Onex Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

REPH

Recro Pharma

$9.73

0.1 (1.04%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Breaking Hot Stocks news story on Recro Pharma »

Recro Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Mar

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:34
03/22/19
03/22
17:34
03/22/19
17:34
General news
White House says hasn't received, been briefed on Mueller report, WSJ says »

Following confirmation…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATS

Catasys

$13.19

-0.39 (-2.87%)

17:26
03/22/19
03/22
17:26
03/22/19
17:26
Syndicate
Breaking Syndicate news story on Catasys »

Catasys files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USWS

U.S. Well Services

$7.74

-0.54 (-6.52%)

17:20
03/22/19
03/22
17:20
03/22/19
17:20
Syndicate
Breaking Syndicate news story on U.S. Well Services »

U.S. Well Services files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.